-The Business Standard The Novartis verdict by the Supreme Court emphasised the importance of flexibilities in drug patent laws, in contrast to Western countries which are seeking TRIPS-plus hardening through free-trade agreements As curtains on the six-year-long legal tussle with Swiss drug giant Novartis AG finally came down earlier this month, the Indian government did not waste a second in hailing the Indian patent law which it said was in "full...

-The Times of India NEW DELHI: With 9,787 regular and 4,447 contract drivers on its payroll, Delhi Transport Corporation has one of the largest resource pools in the city. Unfortunately, these drivers are calling attention to the corporation for all the wrong reasons. Since 2011, the number of accidents involving DTC buses has steadily gone up with a corresponding increase in fatalities. Complaints of rash driving have been pouring in, prompting frequent...

-The Hindu Business Line From maker of versions of drugs, India's pharmaceutical industry has turned a top innovator Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy's key architect and member of its promoter family) and Anji Reddy (founder of Dr Reddy's Laboratories), were alive. And the pharmaceutical industry did not have...

-The Hindu     They say Supreme Court-appointed panel's recommendations reasonable Even as the final report of the Supreme Court-appointed Technical Expert Committee (TEC) on open field trials of genetically modified crops is awaited, 51 independent international scientists with expertise in genetic engineering and biosafety protocols have approved the panel's Interim Report. The report has called for a 10-year moratorium on open field trials of Bt food crops until adequate regulatory mechanisms and safety...

-Economic and Political Weekly While the Supreme Court decision in the recent Novartis case has cleared the way for production of generic drugs in India, doctors have to prescribe cheaper alternatives to costly brands if patients with limited means are to benefit. What is being hailed as a victory in the struggle for affordable medicines in the country will actually be one only when there is a pro-patient slant to the...